All In Biotech

Drug Trial Radar · NCT01770145

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

127

Actual

Start

Dec 2012

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.

Conditions

  • Parkinson's Disease
  • Motor Symptoms
  • Akinesia
  • Hypomobility
  • Delayed Levodopa Onset

Interventions

  • APOKYNDrug

    Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' "best on" UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).

  • L-dopaDrug

    Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.

  • TrimethobenzamideDrug

    Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary.Time frame: L-Dopa Baseline Days 1-7 and APOKYN Treatment Days 1-7

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Keck School of Medicine

    Los Angeles, California

  • Neurosearch, Inc.

    Reseda, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Henry Ford West Bloomfield Hospital

    Bloomfield Hills, Michigan

  • Parkinson's Disease and Movement Disorders Center of New York

    Commack, New York

  • University of Cincinnati Academic Health Center

    Cincinnati, Ohio

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • University of Texas Health Science Center, Houston, Department of Neurology

    Houston, Texas

  • Center for Neurological Care and Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.